Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...
Medical Dialogues22h
Novo Nordisk reshapes Executive management team
Bagsværd: Novo Nordisk HA has announced that Camilla Sylvest has decided to leave the company after a distinguished career of ...
Novo Nordisk: Finally A Buying Opportunity
Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.
pharmaphorum4d
Novo Nordisk sheds billions in value on obesity data
that gave a weight reduction of 22.7% for CagriSema versus 11.8% with cagrilintide alone, 16.1% with semaglutide, and 2.3% with placebo. The design of REDEFINE-1 allowed patients to lower their ...
pharmaphorum2d
High-dose semaglutide ramps up weight loss, says Novo
Phase 3 results reported for CagriSema last month were a disappointment, however, with a 20.4% reduction in weight in the REDEFINE 1 study over 68 weeks that fell short of Novo Nordisk's hope of a ...
Eurogamer3d
Switch 2 release date and price revealed
Nintendo has finally revealed the release date and price of its forthcoming Switch 2 console. The Switch 2 will be released on 5th June and cost £395.99. Pre-orders will open on 8th April ...
Morningstar3d
vopemed Secures $2.29M CAD Pre-Seed Funding to Redefine Surgical Visualization with AI
MONTRÉAL, April 2, 2025 /PRNewswire/ - vopemed (Vope Medical), a pioneering MedTech startup enhancing surgical vision with AI-powered image clarification, has secured an oversubscribed $2.29 ...